NuPathe re-files transdermal Migraine patch at FDA - 02-Aug-2012

FDA has accepted for review the resubmitted new drug application for the transdermal sumatriptan migraine patch NP101 fom NuPathe. The FDA has set 17 January as the new Prescription Drug User Fee Act action date.This will be the first transdermal patch for Migraine ever reviewed by the agency.

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013